Clinical Trial Update: Pazopanib for Treating Uterine Leiomyosarcoma [Phase 2]

View source ↗

Summary

The Phase 2 clinical trial of pazopanib for treating uterine leiomyosarcoma has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Uterine Leiomyosarcoma

Drugs mentioned

• Pazopanib (Votrient) (Pazopanib)

Snippet

Sponsor: Gynecologic Oncology Group | Conditions: Uterine Leiomyosarcoma | Phase 2 | Status: WITHDRAWN